Tirofiban Hydrochloride

Neuroform Atlas stent-assisted coiling yields favorable outcomes in treatment of intracranial aneurysms in arteries less than 2.5 mm in diameter BEIJING, BEIJING, CHINA, January 9, 2026 / EINPresswire.com / -- Aneurysm is the widening or dilation of blood vessels due to weakness of the vessel wall. Such widening of blood vessels can result in rupture of the blood vessel and hemorrhage. If the dilation occurs in blood vessels of the brain, it is referred to as intracranial or cerebral aneurysm. Unruptured intracranial aneurysms can be detected radiologically with advanced medical imaging techniques such as computed tomographic angiography or magnetic resonance angiography. Brain aneurysms are often treated by stent-assisted placement of coils in the dilated area that induce clotting and prevent further bleeding. The Neuroform Atlas stent (NAS) used for stent-assisted coiling is designed for placement in 2.0–4.5 mm vessels. It is not known whether NAS is effective in treatment of aneurysms in smaller blood vessels. A group of researchers led by Professor Rui Xu at the Department of Interventional Radiology, The Affiliated Hospital of Qingdao University, China, sought to address this important clinical question. Explaining the objective of their study, Prof. Xu says, “NAS is a newly developed stent that features the ability to navigate through small and highly tortuous vessels, but there are very few reports on the feasibility and safety of placing NAS in small-diameter vessels.” This study, published in Volume 11 Article number 4 of the Chinese Neurosurgical Journal on February 11, 2025, reports analysis of clinical data from 50 patients with intracranial aneurysms who received NAS in parent arteries of diameter less than 2.5 mm. The researchers collaborated with Shandong University, China and evaluated the follow-up angiography images that included computed tomographic angiography, magnetic resonance angiography, and digital subtraction angiography. Clinical outcomes were analyzed using the modified Raymond-Roy classification and modified Rankin Scale (mRS). The analysis revealed that the NAS-assisted coiling procedure was successful in all patients with majority of the cases achieving complete resolution of the vessel dilation. Only three patients with follow-up reported recurrence of aneurysm, with only one patient requiring an additional procedure. Also, only one patient was observed with poor neurological outcomes. The postoperative complication rates were very low. Treatment complications due to perioperative ischemic (insufficient blood supply) or hemorrhagic events (bleeding from a damaged blood vessel) are a significant limiting factor for stent implantation in small parent arteries. This study recommends the timely postoperative use of antiplatelet medication tirofiban to further reduce the risk of ischemic complications. Additionally, the authors note that based on the patient’s condition, in case of unruptured aneurysms, administering dual antiplatelet therapy preoperatively, and tirofiban intraoperatively are beneficial. Also, in case of ruptured aneurysms, administering tirofiban intraoperatively, and dual antiplatelet therapy postoperatively are effective. Additionally, the authors suggest that when a patient exhibits newer neurological impairments, an immediate computed tomography scanning should be done to identify or rule out the chances of intracranial hemorrhage. If no hemorrhage has been found, then intravenous tirofiban should be administered intravenously. Overall, the study provides preliminary evidence that NAS is safe and effective in arteries smaller than 2.5 mm in diameter. Attributing the favorable outcomes to special features of the ATLAS stent, Prof. Xu clarifies, “Previous stent catheters were not only too rigid to safely reach the target area but also too large in diameter, potentially obstructing blood flow in small vessels, leading to stagnation and subsequent ischemic events. In contrast, the ATLAS stent can be deployed via microcatheters with an inner diameter of 0.0165–0.017 inches.” The absence of direct comparison with other stents used for the same purpose and lack of data from additional centers using NAS, limits the conclusions drawn from this study. Future studies addressing the long-term impact of NAS in smaller blood vessels will benefit clinical practice and expand the utility of NAS in treating aneurysms in both small and medium-sized blood vessels. Reference Titles of original papers: Journal: Preliminary outcomes of Neuroform Atlas stent‑assisted coiling for intracranial aneurysms with small parent vessels Chinese Neurosurgical Journal DOI: 10.1186/s41016-025-00390-x About the University: The Affiliated Hospital of Qingdao University was founded in 1898 and stands as a premier tertiary medical and teaching institution in Qingdao, China. With a strong foundation in clinical excellence, medical education, and scientific research, it operates across multiple campuses and houses over 5,000 beds. The hospital offers advanced care in specialties such as organ transplantation, oncology, and precision medicine. As a major teaching base of Qingdao University, it trains thousands of medical students, residents, and researchers annually. Committed to innovation and global collaboration, the hospital continues to advance healthcare delivery and medical science across China and beyond. Website: https://www.qduh.cn/enhome About the author: Professor Rui Xu is a leading interventional radiologist at The Affiliated Hospital of Qingdao University, where he serves as Deputy Director of the Interventional Medicine Center. His clinical expertise includes neurovascular interventions, such as aneurysm embolization, carotid stenting, and mechanical thrombectomy, as well as tumor-targeted therapies. He has published over 50 academic papers, including several in SCI-indexed journals, and contributed to multiple medical textbooks. Prof. Xu also leads national and provincial research projects and is actively involved in mentoring postgraduate students. His work reflects a strong commitment to advancing minimally invasive therapies and improving outcomes in neurological and oncological care. Yi Lu Chinese Neurosurgical Journal +861059978478 ext. luyi617@sina.cn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

WINNIPEG, MB / ACCESSWIRE / June 24, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announces it has signed an asset purchase agreement ("Agreement") with CanAm Bioresearch Inc. ("CanAm") for the acquisition of the patent and intellectual property related to the discovery of new chemical entities that can be developed for therapeutic use (the "Proposed Transaction"). Medicure believes that the new chemical entities hold promise to provide improvements over existing lead compounds in alignment with the treatment of diseases being targeted by Medicure, and could provide significant value upon completion of all required non-clinical and clinical studies and regulatory approval. These new chemical entities are not being applied in Medicure's current Phase 3 study evaluating the use of MC-1 for the prevention or treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency. Key Terms of the Agreement Pursuant to the Agreement, Medicure International Inc., a wholly owned subsidiary of Medicure, has agreed to acquire, subject to the conditions contained in the Agreement, all of the assets of CanAm as they relate to the business of developing pyridoxal 5'-phosphate analogues ("P5P Analogues"), the processes for their preparation, compositions containing P5P Analogues, and methods of medical treatment containing P5P Analogues (the "Assets"). In consideration for the Assets, Medicure has agreed to pay to CanAm a $100,000 cash payment on the closing date, in addition to the following milestone payments: (i) $500,000, earned upon Medicure filing its first investigational new drug application ("IND Application") related to P5P Analogues; (ii) $250,000, earned upon the Medicure filing its first New Drug Application ("NDA") related to P5P Analogues; and (iii) $500,000, earned upon Medicure obtaining an NDA approval for P5P Analogues. In addition, Medicure shall pay to CanAm 10% of net proceeds received with respect to transactions relating to the Assets, including: (i) the sale or transfer of all or substantially all of the Assets to a third party purchaser who is not an affiliate of Medicure; (ii) any license to develop, commercialize, use, offer for sale, sell, import, export or exploit P5P Analogues up to a maximum value payable to CanAm of $20,000,000; and (iii) the sale of an United State Food and Drug Administration priority review voucher obtained in connection with the development of P5P Analogues. In the event Medicure retains a contract research organization ("CRO") to provide services related to development of P5P Analogues, CanAm, a CRO, would be entitled to tender a bid for such services, in addition to having an opportunity to match quotes for CRO services provided by third-party organizations. In the event that Medicure does not IND Application within 7 years from the closing date of the Proposed Transaction, CanAm shall have the option at any time after such date to repurchase the Assets from Medicure, at a price equal to the aggregate of all expenses incurred by Medicure in connection with the development of P5P Analogues, but, in any event, not exceeding the sum of $6,500,000 USD. Closing of the Proposed Transaction is subject to a number of terms and conditions, including without limitation, CanAm completing certain intellectual property filings with respect to the patent application it holds for P5P Analogues, the parties obtaining all necessary consents, orders and regulatory approvals, including approval of the TSX Venture Exchange ("TSXV"), and certain other customary closing conditions. All dollars are Canadian dollars unless otherwise noted. About CanAm Founded in 2000, CanAm is a privately held medicinal chemistry contract research organization providing drug discovery services, and is located in Winnipeg, Canada. As Medicure's CEO and Chairman of the board of directors, Dr. Albert D. Friesen, is the President and shareholder of the parent company of CanAm, the Proposed Transaction will constitute a "related party transaction" in accordance with Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Proposed Transaction will be exempt from the formal valuation and the minority shareholder approval requirements of MI 61-101, as no securities of Medicure are listed or quoted on any of the specified markets listed in section 5.5(b) of MI 61-101 and, at the time the Proposed Transaction was agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Proposed Transaction, insofar as it involves interested parties, exceeded 25% of Medicure's market capitalization. No finder's fee is expected to be payable in connection with the Proposed Transaction. Due to Dr. Friesen's involvement with CanAm, a special committee (the "Special Committee") of independent directors was established to consider the Proposed Transaction without conflict of interest and to negotiate the terms of the Agreement. The Special Committee unanimously determined that the Proposed Transaction is in the best interests of Medicure and recommended that the board of directors of Medicure approve the Agreement. About Medicure Inc. Medicure is a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug Inc. ("Marley Drug®"), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is committed to improving access to medications for all Americans together with exceptional customer service and free home delivery. For more information visit . For more information about Medicure please visit . For additional information about AGGRASTAT®, please visit or refer to the full Prescribing Information. For additional information about ZYPITAMAG®, please visit or refer to the full Prescribing Information. To be added to Medicure's e-mail list, please visit: Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. More particularly and without limitation, this press release contains forward-looking statements and information regarding the completion of the Proposed Transaction, the acquisition of the Assets by Medicure and the ability of the new chemical compounds acquired to provide improvements over existing lead compounds. Except as may be required by Canadian securities laws, the Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, failure of the parties to satisfy the conditions for the completion of the Proposed Transaction, termination of the Agreement, the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a priority review voucher from the United State Food and Drug Administration, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its current Form 20F. AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAG® (pitavastatin) tablets, and Marley Drug® are registered trademarks. For more information, please contact: Dr. Albert D. Friesen Chief Executive Officer Tel. 888-435-2220 Fax 204-488-9823 E-mail: info@medicure.com SOURCE: Medicure Inc. View the original press release on accesswire.com